• Juan M Abdo-Francis, Guillermo Cabrera-Álvarez, Héctor Martínez-Torres, and José M Remes-Troche.
• Endoscopy Department, Hospital Ángeles Acoxpa, Mexico City.
• Gac Med Mex. 2022 Jan 1; 158 (6): 423429423-429.

IntroductionA national survey in the general population showed that gastroesophageal reflux disease (GERD) is highly prevalent in Mexico.ObjectiveTo compare the efficacy and safety of two isomers, dexrabeprazole (10 mg) vs. esomeprazole (20 mg), in the treatment of GERD for four weeks.MethodsRandomized, multicenter, prospective, double-blind phase III clinical trial in two groups that included 230 patients.ResultsA statistically significant decrease in the severity of GERD symptoms (heartburn, regurgitation, epigastric pain and dysphagia), evaluated using a visual analogue scale, was observed with both treatments. Mean score for dexrabeprazole on Carlsson-Dent questionnaire at 28 days was 2.12, and for esomeprazole, 3.02. Both treatments were effective, with no statistically significant difference being recorded (p < 0.05). On SF-36 health questionnaire, both were observed to improve the quality-of-life score, with no significant difference being identified. Both drugs were well tolerated, and the adverse event incidence profile was low.ConclusionsIn the treatment of non-erosive GERD, the use of dexrabeprazole at 10 mg/day is as effective as esomeprazole 20 mg/day, with the advantage that the dose is lower with an appropriate safety profile.Copyright: © 2022 Permanyer.

15 keywords...

hide…